Standards for the treatment of juvenile, ischemic stroke should not be abandoned for SARS-CoV-2 positives

We read with interest the article by Hashemi et al. about a 12-year-old male with acute ischemic stroke in the territory of the left middle cerebral artery being attributed to SARS-CoV2 related cerebral vasculitis [1]. The patient was treated with acetyl-salicylic acid, steroids, and intravenous immunoglobulins [1]. The long-term outcome of the patient was not provided [1]. The study is appealing but raises concerns that should be discussed. We disagree with the notion that the patient had a status epilepticus (SE) [1]. We should be informed about the clinical manifestations of the SE. Were ever any tonic-clonic contractions observed, was there a tongue bite, was there a secessus alvi or urinae, or was the SE classified as non-convulsive SE Missing in this respect is the electro encephalography (EEG). Were ever epileptiform discharges recorded on EEG? There is a discrepancy between the abstract and the main text [1]. In the abstract, the patient is described with new-onset seizures but in the main text, there is no mentioning of any single seizure [1]. There is also discrepancy between the semiology of seizures [1]. According to the abstract the patient had single seizures, whereas in the main text the patient had SE [1]. These discrepancies should be solved. It is also unclear why the patient initially received phenytoin intravenously which was later switched to levetiracetam. We should be informed why the antiepileptic medication was changed and why the patient was put on a long-term anti-seizure medication without ever recording an EEG